Kura Oncology's Third Quarter Tests Whether ComSifty's Launch Momentum Is Built To Last

Kura Oncology heads into its third-quarter report with an odd disconnect. Management closed the last call sounding more confident than at any point in the past year, claiming market leadership in relapsed or refractory NPM1 acute myeloid leukemia after only two full quarters of selling ComSifty. Yet the stock has slipped since then, and the consensus revenue figure barely moves. The report due after the close on November 10 should show which side has it right: the commercial story, or a market that still wants proof that early prescribing turns into lasting revenue.

Wall Street expects a loss of $0.83 per share, a bit better than the $0.85 loss a year ago but wider than last quarter's $0.77. Revenue is pegged at $22.2 million, up about 7% from a year earlier and only modestly above the second quarter's $20.9 million. That headline number hides the real story. Second-quarter revenue split into roughly $9.1 million of ComSifty sales and $11.8 million of non-cash collaboration revenue, which has been edging lower. Management has held its 2026 collaboration revenue target of $45 million to $55 million all year. With about $24.3 million booked in the first half, the second half needs roughly $10 million to $15 million a quarter. If collaboration revenue keeps slipping toward the low end, then product sales are doing almost all the work in the consensus. Product revenue grew 57% sequentially last quarter, so the forecast doesn't demand much acceleration. The more telling figure will be ComSifty sales on their own.

The operating details matter more than the top line. New patient starts rose from 85 to about 115 last quarter, and total prescriptions jumped more than 60% to over 250. That gap suggests patients are staying on therapy and getting refills. Another clear step up in both measures would support the leadership claim. Prescription growth that outpaces new starts would be the first real evidence for management's assumption of about six months on treatment, which remains untested. Flat new starts, or prescriptions growing in line with starts, would raise the question of whether the early surge came from patients who had been waiting for the drug rather than steady ongoing demand.

Market share is the most contested point. Kura said it won a majority of new NPM1 starts in the same quarter a competitor claimed about two-thirds. Both claims can't hold, so any fresh data on share, prescriber breadth or community-oncology uptake will be closely scrutinized. Payer access gives management some support. Covered lives already exceed 95%, and preferred or step-edit coverage grew to about 16 million lives. About 40% of patients receive the drug in combination regimens that Kura does not promote. That shows doctors are interested, but it also makes demand harder to forecast. On costs, SG&A rose with the commercial build while R&D stayed contained. Any change there affects the reaffirmed cash runway into the 2028 COMET-017 Phase 3 readout. Updates on FLT3 combination data promised for the second half of 2026, and on the newly elevated darlifarnib program, round out the agenda.

Sentiment has warmed noticeably, with bullish readings roughly doubling from the prior quarter. The stock has not followed. Shares are down 7.6% since the last report, trailing the S&P 500 by nearly five points. At $9.79, the stock sits essentially on its 200-day moving average and in the lower part of a post-earnings range that briefly reached $13.90. Traders bid it up on the leadership narrative and then gave much of that back.

The central question is durability. A third straight quarter of strong ComSifty growth, driven by both new starts and repeat prescriptions, would support management's leadership claim and justify last quarter's confidence. A stall would suggest the market was right to stay skeptical.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.